London: British pharmaceutical major GlaxoSmithKline (GSK) has failed to meet the required regulatory and ethical standards ...

By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated ...

GSK's former head of vaccines R&D – Dr Emmanuel ... a vaccine against respiratory syncytial virus (RSV) infections. The London-based company was founded by venture capital firm Medicxi in ...

The London-based pharmaceutical company said Blenrep, or belantamab mafodotin, was approved for the treatment of adult patients with multiple myeloma in combination with bortezomib plus dexamethasone, ...

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon.

LONDON, March 25 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles ...

Britain will invest up to $767 million into a new health data research service to help boost scientific studies and cut the ...

Arexvy, already approved in over 60 countries, was supported by trial data showing safety and immune response in the 50–59 age group. GSK said more than 13 million adults in the US fall into this ...

Ohio and Indiana are suing the makers of a popular heartburn medication, saying the drug company concealed cancer risks and ...

Pfizer denied the allegations and argued GSK's patents were invalid. It convinced a London court to invalidate related UK patents owned by GSK in a separate case last year. GSK has also sued ...